We are live on !
Find out more
Brandywine Managers Portfolio holdings
AUM
$202M
Turnover
13.04%
1-Year Est. Return
16.99%
This Fund
S&P 500
This Quarter Est. Return
+0.85%
1 Year Est. Return
+16.99%
3 Year Est. Return
+96.29%
5 Year Est. Return
+26.97%
10 Year Est. Return
+345.77%
AUM
$28.6M
AUM Growth
-$1.78M
(-5.9%)
Cap. Flow
-$13.2K
Cap. Flow % of AUM
Cap. Flow %
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
60.06%
Holding
41
New
2
Increased
3
Reduced
2
Closed
4
Avg Time Held
3.1
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prime Medicine
PRME
|
+$596K |
| 2 |
Mobileye
MBLY
|
+$397K |
| 3 |
CrowdStrike
CRWD
|
+$122K |
| 4 |
Guardant Health
GH
|
+$120K |
| 5 |
Twist Bioscience
TWST
|
+$97.7K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ionis Pharmaceuticals
IONS
|
+$374K |
| 2 |
Varonis Systems
VRNS
|
+$360K |
| 3 |
Beam Therapeutics
BEAM
|
+$224K |
| 4 |
SentinelOne
S
|
+$202K |
| 5 |
Seer Inc
SEER
|
+$119K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 55.54% |
| 2 | Healthcare | 34.04% |
| 3 | Consumer Staples | 4.76% |
| 4 | Financials | 3.34% |
| 5 | Consumer Discretionary | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
UiPath
PATH
$7.4B
| $5.53M | 19.31% |
434,841
| – | – |
2021 Q2
6 quarters
|
|
|
2
CrowdStrike
CRWD
$273B
| $3.02M | 10.55% |
114,720
+3,552
| +3% | +$122K |
2019 Q2
14 quarters
|
|
3
Moderna
MRNA
$85.5B
| $1.71M | 5.97% |
9,510
| – | – |
2018 Q4
16 quarters
|
|
4
Campbell Soup
CPB
$6.14B
| $1.36M | 4.76% |
24,014
| – | – |
2014 Q3
33 quarters
|
|
5
Alnylam Pharmaceuticals
ALNY
$31.1B
| $1.1M | 3.83% |
4,608
| – | – |
2018 Q4
16 quarters
|
|
6
Mastercard
MA
$535B
| $956K | 3.34% |
2,750
| – | – |
2022 Q2
2 quarters
|
|
7
Intuitive Surgical
ISRG
$157B
| $927K | 3.24% |
3,495
| – | – |
2017 Q3
21 quarters
|
|
8
Salesforce
CRM
$199B
| $917K | 3.2% |
6,913
| – | – |
2020 Q3
9 quarters
|
|
9
Natera
NTRA
$61.2B
| $865K | 3.02% |
21,534
| – | – |
2017 Q3
21 quarters
|
|
10
PagerDuty
PD
$1.41B
| $811K | 2.83% |
30,517
| – | – |
2019 Q2
14 quarters
|
|
11
Zscaler
ZS
$41.7B
| $783K | 2.74% |
7,000
| – | – |
2018 Q4
16 quarters
|
|
12
Okta
OKTA
$38.9B
| $700K | 2.45% |
10,248
| – | – |
2017 Q3
21 quarters
|
|
13
Veeva Systems
VEEV
$51.5B
| $632K | 2.21% |
3,919
| – | – |
2017 Q2
22 quarters
|
|
|
14
Prime Medicine
PRME
$972M
| $613K | 2.14% |
+32,977
| New | +$596K |
2022 Q4
0 quarters
|
|
15
AbCellera Biologics
ABCL
$4.42B
| $577K | 2.02% |
56,976
| – | – |
2020 Q4
8 quarters
|
|
16
Datadog
DDOG
$100B
| $529K | 1.85% |
7,200
| – | – |
2019 Q3
13 quarters
|
|
17
Advanced Micro Devices
AMD
$944B
| $525K | 1.83% |
8,099
| – | – |
2022 Q1
3 quarters
|
|
18
NVIDIA
NVDA
$5.2T
| $521K | 1.82% |
35,640
| – | – |
2020 Q1
11 quarters
|
|
19
Palo Alto Networks
PANW
$323B
| $517K | 1.81% |
7,410
| – | – |
2020 Q2
10 quarters
|
|
|
20
Twist Bioscience
TWST
$11.5B
| $499K | 1.74% |
20,970
+3,371
| +19% | +$97.7K |
2018 Q4
16 quarters
|
|
21
Twilio
TWLO
$39B
| $479K | 1.67% |
9,782
| – | – |
2018 Q1
19 quarters
|
|
22
Relay Therapeutics
RLAY
$4.31B
| $475K | 1.66% |
31,807
| – | – |
2020 Q3
9 quarters
|
|
|
23
Mobileye
MBLY
$6B
| $458K | 1.6% |
+13,067
| New | +$397K |
2022 Q4
0 quarters
|
|
|
24
Guardant Health
GH
$24.5B
| $433K | 1.51% |
15,933
+2,625
| +20% | +$120K |
2018 Q4
16 quarters
|
|
25
10x Genomics
TXG
$10.9B
| $408K | 1.43% |
11,208
| – | – |
2019 Q3
13 quarters
|
|
Similar funds
OPL
LAMC
Brandywine Managers's Q4 2022 Portfolio in Review
As of Q4 2022, Brandywine Managers held 41 positions worth $28.6M, down 5.9% from $30.4M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Brandywine Managers's Q4 2022 filing shows 2 new, 3 increased, 2 reduced and 4 closed positions. Its largest new stake was Prime Medicine: 32,977 shares worth $613K. The largest sale was Ionis Pharmaceuticals, an estimated $374K.
By sector, the portfolio is most concentrated in Technology at 56% of assets, down from 61% a quarter earlier, followed by Healthcare and Consumer Staples.
- Brandywine Managers's largest Q4 2022 buy was Prime Medicine: 32,977 shares worth $613K.
- Brandywine Managers added most to CrowdStrike in Q4 2022, an estimated $122K increase.
- Brandywine Managers's biggest Q4 2022 reduction was Beam Therapeutics, cutting an estimated $224K.
- Brandywine Managers fully exited Ionis Pharmaceuticals in Q4 2022, selling an estimated $374K.
- Brandywine Managers's ten largest holdings make up 60% of its $28.6M portfolio in Q4 2022.
- Brandywine Managers opened 2 new positions and closed 4 in Q4 2022.
- Brandywine Managers's portfolio value fell 5.9% quarter-over-quarter to $28.6M.
Based on Brandywine Managers's 13F filing for Q4 2022, filed 14 Feb 2023.